Douglas Miehm
Stock Analyst at RBC Capital
(3.92)
# 1,880
Out of 4,690 analysts
409
Total ratings
50.5%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: APTX Apotex Health Corp. | Maintained: Buy | $43.00 | $31.87 | +34.92% | 3 | Aug 12, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Maintained: Buy | $21.00 | $17.42 | +20.55% | 42 | Aug 10, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $345 | $280.49 | +23.00% | 21 | Aug 9, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 → $16 | $16.29 | -1.78% | 44 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $9.50 → $11.00 | $9.47 | +16.16% | 28 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Maintained: Hold | $19.00 | $15.45 | +22.98% | 47 | Aug 7, 2026 | |
| MNKD MannKind | Maintained: Hold | $4.75 | $3.95 | +20.25% | 10 | Aug 6, 2026 | |
| PCRX Pacira BioSciences | Maintained: Hold | $24 → $25 | $25.76 | -2.95% | 6 | Aug 5, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Hold | $12.52 | $8.78 | +42.58% | 104 | Jul 30, 2026 | |
| BLCO Bausch + Lomb | Maintained: Buy | $21 | $17.15 | +22.45% | 38 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.00 | $4.34 | +61.29% | 22 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7.91 | $18.04 | -56.16% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2.52 → $3.5 | $0.8566 | +308.59% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $4.59 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €22.00 | €97.40 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $8.10 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 |
Apotex Health Corp.
Aug 12, 2026
Maintained: Buy
Price Target: $43.00
Current: $31.87
Upside: +34.92%
DRI Healthcare Trust
Aug 10, 2026
Maintained: Buy
Price Target: $21.00
Current: $17.42
Upside: +20.55%
Ligand Pharmaceuticals
Aug 9, 2026
Reiterated: Buy
Price Target: $345
Current: $280.49
Upside: +23.00%
Aurinia Pharmaceuticals
Aug 7, 2026
Maintained: Hold
Price Target: $15 → $16
Current: $16.29
Upside: -1.78%
Knight Therapeutics Inc.
Aug 7, 2026
Maintained: Buy
Price Target: $9.50 → $11.00
Current: $9.47
Upside: +16.16%
Medical Facilities Corporation
Aug 7, 2026
Maintained: Hold
Price Target: $19.00
Current: $15.45
Upside: +22.98%
MannKind
Aug 6, 2026
Maintained: Hold
Price Target: $4.75
Current: $3.95
Upside: +20.25%
Pacira BioSciences
Aug 5, 2026
Maintained: Hold
Price Target: $24 → $25
Current: $25.76
Upside: -2.95%
Bausch Health Companies Inc.
Jul 30, 2026
Reiterated: Hold
Price Target: $12.52
Current: $8.78
Upside: +42.58%
Bausch + Lomb
Jul 30, 2026
Maintained: Buy
Price Target: $21
Current: $17.15
Upside: +22.45%
May 10, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.34
Upside: +61.29%
Mar 19, 2026
Maintained: Buy
Price Target: $7.91
Current: $18.04
Upside: -56.16%
Nov 19, 2025
Maintained: Buy
Price Target: $2.52 → $3.5
Current: $0.8566
Upside: +308.59%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $4.59
Upside: n/a
Jun 23, 2021
Maintained: Buy
Price Target: €22.00
Current: €97.40
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $8.10
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a